Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Journal of Diabetes and Metabolic Disorders

Volumn 14, Issue 1, 2015, Pages

  Tamez, Hector E ^a   Tamez, Alejandra L ^a   Garza, Lucas A ^a   Hernandez, Mayra I ^a   Polanco, Ana C ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Dapagliflozin; Insulin; Type 1 diabetes mellitus

Indexed keywords

CHOLESTEROL; DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADULT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; LIPID ANALYSIS; MALE; METABOLIC REGULATION; TREATMENT DURATION; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84943329171     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/s40200-015-0210-x     Document Type: Letter

References (16)

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL, on behalf of the Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034-54.
2. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011;60:1-8. doi:10.2337/db10-1114.
3. Orlando G, Gianello P, Salvatori M, Stratta RJ, Soker S, Ricordi C, et al. Cell replacement strategies aimed at reconstitution of the β-cell compartment in type 1 diabetes. Diabetes. 2014;63:1433-44. doi:10.2337/db13-1742.
4. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014;5:265-75. doi:10.1111/jdi.12214.
5. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23:875-82.
6. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975-87. doi:10.1111/jphp.12223.
7. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. doi:10.1186/1475-2840-13-28.
8. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480-3. doi:10.2337/dc13-2338.
9. American Diabetes Association. Diagnosis and classifications of diabetes mellitus. Diabetes Care. 2014;37:S81-90. doi:10.2337/dc14-S081.
10. Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014. doi:10.1111/dom.12327.
11. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2:CD009122. doi:10.1002/14651858.CD009122.pub2.
12. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, et al. Pramlintide improved measures of glycemic control and body weight inpatients with type 1 diabetes mellitus undergoing continuous subcutaneousinsulin infusion therapy. Postgrad Med. 2013;125(3):136-44.
13. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-74.
14. Mudaliar S, Armstrong DA, Mavian AA, O'Connor-Semmes R, Mydlow PK, Ye J, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35:2198-200. doi:10.2337/dc12-0508.
15. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebocontrolled pilot study. Diabetes Care. 2014;38(3):412-9. DC_132955.
16. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638-42. doi:10.2337/dc15-1380.